BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230829
DTEND;VALUE=DATE:20230902
DTSTAMP:20260516T065813
CREATED:20230503T044916Z
LAST-MODIFIED:20230503T044916Z
UID:37116-1693267200-1693612799@www.pharmajournalist.com
SUMMARY:8th CAR-TCR Summit
DESCRIPTION:Last year was momentous for the cell therapy field: it was the year that CAR-T therapies became CURATIVE. \nThis decade of success has resulted in explosive investment into the development of CAR and TCR based approaches to ensure more patients around the world can benefit from these lifesaving therapies.   \nThe 8th CAR-TCR Summit is returning to Boston as the industry’s trusted\, definitive\, end-to-end forum for the global network of autologous and allogeneic cell therapy drug developers. Ensure your whole team stays ahead of the curve with unmatched industry insights shared across discovery through to commercialization.   \nAcross 3 conference days with 8 content tracks\, and an additional 6 deep-dive workshops\, bootcamp\, focus day\, diversity session\, C-level think tank and more\, 200+ CAR and TCR experts will lead you and over 1\,000 peers in discussions that will accelerate your pipeline\, bringing better drugs to patients faster. \nTo know more visit: https://ter.li/ztgick
URL:https://www.pharmajournalist.com/event/8th-car-tcr-summit/
LOCATION:Hynes Convention Center\, 900 Boylston St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230829
DTEND;VALUE=DATE:20230901
DTSTAMP:20260516T065813
CREATED:20230516T102107Z
LAST-MODIFIED:20230517T113503Z
UID:37184-1693267200-1693526399@www.pharmajournalist.com
SUMMARY:2nd Oligonucleotides CMC & Analytical Development Summit 2023
DESCRIPTION:Rapid development and rising demand of oligonucleotide drugs is fuelling revolutionary steps in biopharma investment and technology advancement for pipeline progression. The prospect of defining impurities and suitable CQAs for long-term scalable manufacturing looks to propel oligonucleotide development to patients at a much faster rate. \nThe 2nd Oligonucleotides CMC & Analytical Development Summit returns this August to Boston. 70+ industry leaders will unite at this unique forum dedicated to CMC and Analytical Experts. \nAcross 3 days\, senior leaders will leverage knowledge and share thought leadership focused on improving analytical characterization\, effectively preparing CMC data for IND filing and scaling up with long-term manufacturing in mind. \nBuilt with experts from AstraZeneca\, Alexion Pharmaceuticals\, Biogen \, revolutionize your drug development protocols by keeping your finger on the pulse at this hotly anticipated summit. \n\nExplore analytical control strategies for therapeutic oligonucleotides to ensure safety and quality with regulatory compliance\nOvercome the challenges of capacity when out-sourcing to propel and expedite oligonucleotide development\nGet interactive in roundtable discussions\, picking the brains of your peers and expert speakers on how biopharma is currently navigating the regulatory landscape\nFacilitate cost-efficient large-scale production of oligonucleotides now we are moving into larger patient populations and non-rare disease indications\nTurbocharge novel and complex oligonucleotide development in an in-depth workshop outlining CMC\, Analytical Characterization and Impurity Control of conjugates\n\nDownload your Full Event Guide Here for more details on what you can expect at the 2nd Oligonucleotides CMC & Analytical Development Summit. Including the expert speaker faculty\, a full in-depth agenda and the incredible networking and collaboration opportunities on offer this year.
URL:https://www.pharmajournalist.com/event/2nd-oligonucleotides-cmc-analytical-development-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230829
DTEND;VALUE=DATE:20230901
DTSTAMP:20260516T065813
CREATED:20230516T103454Z
LAST-MODIFIED:20230516T103454Z
UID:37187-1693267200-1693526399@www.pharmajournalist.com
SUMMARY:3rd Inner Ear Disorders Therapeutics Summit
DESCRIPTION:The development of next-generation drug-based approaches to treat inner ear disorders is gaining momentum\, with multiple INDs approved in the last six months and big pharma making plays to acquire innovative biotechs working on hearing loss. \nHowever\, in a space that has also had to battle with multiple clinical failures\, there’s a genuine need for the industry to unite and overcome the specific obstacles that are currently acting as a barrier to late-stage clinical trials and through to approval. \nThat’s why the 3rd Inner Ear Disorders Therapeutics Summit is back this summer\, bringing together the community to collectively accelerate development of drug-based approaches\, sharing case studies and data-driven insights into optimizing preclinical programs and designing translational studies to ultimately validate clinically relevant targets. \nThis meeting will leverage the latest biotech and academic innovation alongside big pharma experience to address the technical and strategic challenges in delivering a safe and effective therapy to the inner ear. \nWhat to expect from the 2023 meeting: \n\nExplore how to improve clinical trial design to increase the number of clinical trials achieving regulatory approval\nDelve into the numerous delivery methods being employed in industry and explore how to optimize delivery to the inner ear\nEvaluate the current opportunities and limitations of using animal models to accurately predict preclinical efficacy and translational success\nLeverage valuable insights from VC investors to understand the key considerations made when investing in or forging partnerships with biotechs focussing on inner ear disorder therapeutics\nNavigate the complex landscape of improving the diagnostics of inner ear disorders by developing a robust diagnostic toolbox and strategizing how to supplement patient-reported outcome measures\n\nView the full agenda here: https://ter.li/a2ivra
URL:https://www.pharmajournalist.com/event/3rd-inner-ear-disorders-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR